When was ASLAN Pharmaceuticals founded?

ASLAN Pharmaceuticals was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is ASLAN Pharmaceuticals located?

ASLAN Pharmaceuticals is headquartered in Singapore, Singapore. It is registered at 83 CLEMENCEAU AVENUE #12-03 UE SQUARE SINGAPORE 239920.

Who is the current CEO of ASLAN Pharmaceuticals?

Carl Firth of ASLAN Pharmaceuticals.

How many employees does ASLAN Pharmaceuticals have?

As of Apr 19, 2024, the latest employee count at ASLAN Pharmaceuticals is 43.

Is ASLAN Pharmaceuticals a funded company?

ASLAN Pharmaceuticals is a funded company, having raised a total of $100M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 27, 2010.

When was the latest funding round of ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals' latest funding was a $***** Post IPO round on Mar 02, 2023, with participation from 2 investors.

Where does ASLAN Pharmaceuticals rank among its competitors?

ASLAN Pharmaceuticals ranks 2nd amongst 14 active competitors, of which 4 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was TIRmed Pharma, which secured an undisclosed amount in Apr, 2025.

Who are the top competitors of ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals' top competitors include RAPT, Concerto Biosciences and UNION Therapeutics. Among them, TIRmed Pharma secured the most recent funding round in April, 2025.

ASLAN Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

ASLAN Pharmaceuticals is an oncology-focused company developing a portfolio of targeted drugs, focusing on gastric, bile duct and breast cancers. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN’s most advanced compounds are ASLAN001 which is pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer, and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET receptor tyrosine kinases, being developed in gastric and breast cancer.

Website: aslanpharma.com
Social
Registered Address: 83 CLEMENCEAU AVENUE #12-03 UE SQUARE SINGAPORE 239920

Key Metrics

Founded Year

2010

Location

Singapore, Singapore

Stage

Public

Total Funding

$100M in 9 rounds

Latest Funding Round

Post IPO, Mar 02, 2023, $*****

Investors

MVP Capital Partners & 16 more

Ranked

2^nd among 14 active competitors

Employee Count

43 as on Apr 19, 2024

Similar Companies

RAPT & 14 more

Exit Details

Public

View ASLAN Pharmaceuticals' full profile

ASLAN Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Aslan Pharmaceuticals Pte Ltd CIN: 201007695N , Singapore, Active	Dec 31, 2009	-	-

ASLAN Pharmaceuticals got listed on Dec 06, 2019.

Click here to take a look at ASLAN Pharmaceuticals's IPO in detail

ASLAN Pharmaceuticals has raised a total funding of $100M over 9 rounds. Its first funding round was on Jul 27, 2010. Its latest funding round was a Post IPO round on Mar 02, 2023 for $*****. 2 investors participated in its latest round. ASLAN Pharmaceuticals has 17 institutional investors.

Here is the list of recent funding rounds of ASLAN Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 02, 2023	9597202	Post IPO	9917796	5506995	5856922	9748304
Feb 25, 2021	4999895	Post IPO	8258413	7549276	9606602	4361444
Oct 18, 2019	5089206	Conventional Debt	7318490	1907966	5079918	1314197

Access funding benchmarks and valuations. Sign up today!

View details of ASLAN Pharmaceuticals's funding rounds and investors

The founders of ASLAN Pharmaceuticals is Carl Firth.

Here are the details of ASLAN Pharmaceuticals' key team members:

Carl Firth: Founder & CEO of ASLAN Pharmaceuticals.

View details of ASLAN Pharmaceuticals's Founder profiles and Board Members

ASLAN Pharmaceuticals' employee count trend

ASLAN Pharmaceuticals has 43 employees as of Apr 24. Here is ASLAN Pharmaceuticals's employee count trend over the years:

Employee count trend for ASLAN Pharmaceuticals

Uncover ASLAN Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ASLAN Pharmaceuticals include RAPT, Concerto Biosciences and UNION Therapeutics. Here is the list of Top 10 competitors of ASLAN Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	RAPT 2015, San Francisco (United States), Acquired	Provider of immunology-based drug for oncology and inflammatory diseases	$199M	The Column Group, Celgene & 19 others	61/100
2nd	ASLAN Pharmaceuticals 2010, Singapore (Singapore), Public	Targeted small molecules for cancer treatment	$100M	BVF Partners, Sagamore Investment Management ... & 15 others	58/100
3rd	Concerto Biosciences 2019, Cambridge (United States), Series A	Developer of microbe-based products for agriculture and human health	$24.5M	Safar Partners, 8VC & 9 others	56/100
4th	UNION Therapeutics 2013, Hellerup (Denmark), Series B	Developer of small molecule antibiotic drugs for treating bacterial infections	$57.1M	European Investment Bank & 8 others	56/100
5th	Biosion 2017, Nanjing (China), Series B	Developer of antibody-based therapeutics to treat various diseases	$76.4M	GF Xinde Investment Management, 3E BioVentures ... & 7 others	56/100
6th	Forte Biosciences 2017, Torrance (United States), Public	Developer of therapeutic solutions for treating inflammatory skin diseases	-	The Red Hook Fund, BVF Partners & 6 others	51/100
7th	PinCell 2008, Milano (Italy), Acquired	Developer of anti-inflammatory therapy for the treatment skin diseases	$1.78M	Sofinnova Partners	44/100
8th	TIRmed Pharma 2018, Bromma (Sweden), Series A	Developer of therapeutic solutions to treat atopic dermatitis	$4.73M	Almi Invest, EIC Fund & 3 others	42/100
9th	Minghui Pharmaceutical 2018, Hangzhou (China), Unfunded	Developer of therapeutics for cancer and auto-immune diseases	-	-	42/100
10th	Golden Biotechnology 2002, Taipei (Taiwan), Public	Developer of drug candidates for treating Alzheimer's disease, hepatitis B, and dermatitis	-	-	30/100